PDCD1 and neoplasm: In addition, we performed analysis of data from various tumor tissues in the TCGA database to analyze the BCL-2 expression level in patients who received immunotherapy and observed that responders to anti-PD-1 treatment had BCL-2 expression levels comparable to those in nonresponders (Fig. 1K–N).